Search

The not-for-profit healthcare organization Hackensack Meridian Health has invested in the phage biotech company Adaptive Phage Therapeutics (APT). According to APT's CEO, Greg Merril, "The high level of interest from strategic and financial

The 2nd Hanson Wade Bacteriophage Therapy Summit will take place March 24-26, 2020 in Boston. Key speakers include representatives from the FDA and the EMA, as well as leaders of several phage biotech companies.

Phage Futures Congress 2020 is happening Feb 5-6, 2020 in Washington, DC. Early bird pricing ends Dec 6. Use discount code 'PHAGEDIRECTORY' for an extra 10% off! Hope to see you there!

Congratulations to Dr. Minmin Yen, CEO of PhagePro, a company developing a phage cocktail as a household cholera prophylactic — she just won $10,000 in the 2019 TropMed pitch competition hosted by the American Society for Tropical Medicine

Congratulations to Dr. Minmin Yen, CEO of PhagePro, a company developing a phage cocktail as a household cholera prophylactic — she just won $10,000 in the 2019 TropMed pitch competition hosted by the American Society for Tropical Medicine

Phage Futures Congress 2020 is happening Feb 5-6, 2020 in Washington, DC. Early bird pricing ends Dec 6. Use discount code 'PHAGEDIRECTORY' for an extra 10% off! Hope to see you there!

In collaboration with researchers at Brunel University London, a new UK synthetic biology company called CC Bio is developing phage lysins to target bacterial vaginosis caused by Gardnerella vaginalis. They've just received £250,000 in fund

Felix Biotechnology is a new phage company using phages to target antibiotic resistant bacteria based on their mechanism of antibiotic resistance (working with Yale University). They just won this year's Falling Walls Venture competition in

In collaboration with researchers at Brunel University London, a new UK synthetic biology company called CC Bio is developing phage lysins to target bacterial vaginosis caused by Gardnerella vaginalis. They've just received £250,000 in fund

Felix Biotechnology is a new phage company using phages to target antibiotic resistant bacteria based on their mechanism of antibiotic resistance (working with Yale University). They just won this year's Falling Walls Venture competition in

BiomX just presented preclinical data on its development of a phage cocktail active against Klebsiella pneumoniae strains correlated with primary sclerosing cholangitis (PSC) severity. PSC is a liver disease with no FDA-approved treatment t

One of Intralytix's phage products, EcoShield (which targets E. coli O157:H7), has been approved by the FDA to be used more broadly. Now it can be used on ground beef (plus other meat cuts and on carcasses). Previously, it could only be use

BiomX just presented preclinical data on its development of a phage cocktail active against Klebsiella pneumoniae strains correlated with primary sclerosing cholangitis (PSC) severity. PSC is a liver disease with no FDA-approved treatment t

One of Intralytix's phage products, EcoShield (which targets E. coli O157:H7), has been approved by the FDA to be used more broadly. Now it can be used on ground beef (plus other meat cuts and on carcasses). Previously, it could only be use

PhagoMed is looking for a high calibre business developer to join our team in Vienna, Austria. Role description: - Identify new business opportunities, incl. analyzing new indications to pursue, grant opportunities, co-development programs

PhagoMed is looking for a high calibre business developer to join our team in Vienna, Austria. Role description: - Identify new business opportunities, incl. analyzing new indications to pursue, grant opportunities, co-development programs

Armata Pharmaceuticals has addressed its shareholders with good news about how their company is progressing post-merger between C3J and AmpliPhi. The company also recently announced that it has received a Research and Development Tax Incent

Armata Pharmaceuticals has addressed its shareholders with good news about how their company is progressing post-merger between C3J and AmpliPhi. The company also recently announced that it has received a Research and Development Tax Incent

Another publicly-traded phage company is now on the stock market! This week, the phage/microbiome biotech company BiomX completed its merger with Chardan Healthcare, and the combined company (BiomX Inc.) started trading on the New York Stoc

Another publicly-traded phage company is now on the stock market! This week, the phage/microbiome biotech company BiomX completed its merger with Chardan Healthcare, and the combined company (BiomX Inc.) started trading on the New York Stoc